Advertisement

Archives of Dermatological Research

, Volume 311, Issue 4, pp 299–308 | Cite as

Malondialdehyde and advanced oxidation protein products are not increased in psoriasis: a controlled study

  • I. M. Skoie
  • I. Dalen
  • R. OmdalEmail author
  • G. Jonsson
Original Paper
  • 52 Downloads

Abstract

This study investigated oxidative stress in patients with psoriasis of low and medium disease activity. We measured advanced oxidation protein products (AOPP) and malondialdehyde (MDA) in plasma using UV-spectrophotometry and high performance liquid chromatography connected to a fluorescence detector in 84 patients and 84 matched healthy subjects. AOPP is a marker of protein oxidation due to inflammation, whereas MDA is a hydroxyl radical initiated lipid peroxidation product. Clinico-demographic variables including age, gender, disease severity, and fatigue were assessed in relation to AOPP and MDA. Disease severity was evaluated with the Psoriasis Area and Severity Index and the Dermatology Life Quality Index. Median (interquartile range, IQR) AOPP concentrations were 66 µmol/l (IQR 54–102) in patients and 69 µmol/l (IQR 55–87) in healthy subjects (P = 0.75). Median plasma MDA concentrations were significantly lower in patients than in healthy subjects (0.68 µM, IQR 0.54–0.85 vs. 0.76 µM, IQR 0.60–0.97; P = 0.03). Plasma levels of AOPP and MDA did not indicate oxidative stress in patients with mild psoriasis. Higher AOPP concentrations were associated with male gender, high body mass index, and high hemoglobin values. Elevated MDA concentrations were associated with advanced age and male gender. No associations with disease severity were detected. Although, the two selected biomarkers do not provide a complete measure of oxidative damage, our study demonstrates that a number of physiological and methodological factors influence the levels of MDA and AOPP. Such methodological issues are important to consider when interpreting results using these biomarkers in patients with psoriasis.

Keywords

Oxidative stress Advanced oxidation protein products AOPP Malondialdehyde MDA Psoriasis 

Abbreviations

AOPP

Advanced oxidation protein products

MDA

Malondialdehyde

ROS

Reactive oxygen species

IQR

Interquartile range

PASI

Psoriasis area and severity index

QoL

Quality of life

DLQI

Dermatology life quality index

fVAS

Fatigue visual analog scale

HADS-D

The depression subscale of the Hospital Anxiety and Depression Scale

TBARS

Thiobarbituric acid reactive substances

HPLC-F

High-performance liquid chromatography connected to a fluorescence detector

Notes

Funding

Inger Marie Skoie received support as a doctoral research fellow from the Western Norway Regional Health Authority (WNRA, “Helse Vest”), Grant number (912015).

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest.

Ethical approval

This study was approved by the Regional Committee for Medical Research Ethics in Norway (REK vest 2010/1455). All participants provided written informed consent, and the study was conducted in accordance with the latest revision of the Helsinki Declaration.

Supplementary material

403_2019_1903_MOESM1_ESM.pdf (82 kb)
Supplementary material 1 (PDF 81 KB)
403_2019_1903_MOESM2_ESM.pdf (96 kb)
Supplementary material 2 (PDF 96 KB)

References

  1. 1.
    Akkara Veetil BM, Matteson EL, Maradit-Kremers H, McEvoy MT, Crowson CS (2012) Trends in lipid profiles in patients with psoriasis: a population-based analysis. BMC Dermatol 12:20.  https://doi.org/10.1186/1471-5945-12-20 CrossRefGoogle Scholar
  2. 2.
    Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H et al (2012) Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol 167:1279–1286.  https://doi.org/10.1111/j.1365-2133.2012.11170.x CrossRefGoogle Scholar
  3. 3.
    Attwa E, Swelam E (2011) Relationship between smoking-induced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 25:782–787.  https://doi.org/10.1111/j.1468-3083.2010.03860.x CrossRefGoogle Scholar
  4. 4.
    Barygina VV, Becatti M, Soldi G, Prignano F, Lotti T, Nassi P et al (2013) Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-alpha therapy. Redox Rep 18:100–106.  https://doi.org/10.1179/1351000213Y.0000000045 CrossRefGoogle Scholar
  5. 5.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefGoogle Scholar
  6. 6.
    Breusing N, Grune T, Andrisic L, Atalay M, Bartosz G, Biasi F et al (2010) An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples. Free Radic Res 44:1203–1215.  https://doi.org/10.3109/10715762.2010.499907 CrossRefGoogle Scholar
  7. 7.
    Briganti S, Picardo M (2003) Antioxidant activity, lipid peroxidation and skin diseases. What’s new. J Eur Acad Dermatol Venereol 17:663–669CrossRefGoogle Scholar
  8. 8.
    Cai Y, Fleming C, Yan J (2012) New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 9:302–309.  https://doi.org/10.1038/cmi.2012.15 CrossRefGoogle Scholar
  9. 9.
    Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A (2006) Biomarkers of oxidative damage in human disease. Clin Chem 52:601–623.  https://doi.org/10.1373/clinchem.2005.061408 CrossRefGoogle Scholar
  10. 10.
    Davies MJ (2011) Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention. J Clin Biochem Nutr 48:8–19.  https://doi.org/10.3164/jcbn.11-006FR CrossRefGoogle Scholar
  11. 11.
    Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T (2013) Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 169:266–282.  https://doi.org/10.1111/bjd.12355 CrossRefGoogle Scholar
  12. 12.
    Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S (2014) Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med 14:431–437.  https://doi.org/10.1007/s10238-013-0252-7 CrossRefGoogle Scholar
  13. 13.
    Farrell CJ, Carter AC (2016) Serum indices: managing assay interference. Ann Clin Biochem 53:527–538.  https://doi.org/10.1177/0004563216643557 CrossRefGoogle Scholar
  14. 14.
    Finlay AY (2005) Current severe psoriasis and the rule of tens. Br J Dermatol 152:861–867.  https://doi.org/10.1111/j.1365-2133.2005.06502.x CrossRefGoogle Scholar
  15. 15.
    Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH et al (2014) BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 30:251–262.  https://doi.org/10.1185/03007995.2013.849236 CrossRefGoogle Scholar
  16. 16.
    Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244CrossRefGoogle Scholar
  17. 17.
    Gabr SA, Al-Ghadir AH (2012) Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Arch Dermatol Res 304:451–457.  https://doi.org/10.1007/s00403-012-1230-8 CrossRefGoogle Scholar
  18. 18.
    Giustarini D, Dalle-Donne I, Tsikas D, Rossi R (2009) Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 46:241–281.  https://doi.org/10.3109/10408360903142326 CrossRefGoogle Scholar
  19. 19.
    Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine, 4th edn. Oxford University Press, OxfordGoogle Scholar
  20. 20.
    Hanasand M, Omdal R, Norheim KB, Goransson LG, Brede C, Jonsson G (2012) Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta 413:901–906.  https://doi.org/10.1016/j.cca.2012.01.038 CrossRefGoogle Scholar
  21. 21.
    Khoubnasabjafari M, Ansarin K, Jouyban A (2016) Critical review of malondialdehyde analysis in biological samples. Curr Pharm Anal 12:4–17.  https://doi.org/10.2174/1573412911666150505185343 CrossRefGoogle Scholar
  22. 22.
    Kilinc Karaarslan I, Girgin Sagin F, Ertam I, Alper S, Ozturk G, Yildirim Sozmen E (2006) Broad-band ultraviolet B phototherapy is associated with elevated serum thiobarbituric acid reactive substance and nitrite-nitrate levels in psoriatic patients. J Eur Acad Dermatol Venereol 20:1226–1231.  https://doi.org/10.1111/j.1468-3083.2006.01765.x CrossRefGoogle Scholar
  23. 23.
    Krzystek-Korpacka M, Patryn E, Boehm D, Berdowska I, Zielinski B, Noczynska A (2008) Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 41:943–949.  https://doi.org/10.1016/j.clinbiochem.2008.04.024 CrossRefGoogle Scholar
  24. 24.
    Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN et al (2012) Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Investig Dermatol 132:556–562.  https://doi.org/10.1038/jid.2011.365 CrossRefGoogle Scholar
  25. 25.
    Lee KH, Bartsch H, Nair J, Yoo DH, Hong YC, Cho SH et al (2006) Effect of short-term fasting on urinary excretion of primary lipid peroxidation products and on markers of oxidative DNA damage in healthy women. Carcinogenesis 27:1398–1403.  https://doi.org/10.1093/carcin/bgi337 CrossRefGoogle Scholar
  26. 26.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRefGoogle Scholar
  27. 27.
    Lykkesfeldt J (2001) Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem 47:1725–1727Google Scholar
  28. 28.
    Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21:103–115.  https://doi.org/10.1038/cr.2010.178 CrossRefGoogle Scholar
  29. 29.
    Mykletun A, Stordal E, Dahl AA (2001) Hospital Anxiety and Depression (HAD) Scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 179:540–544CrossRefGoogle Scholar
  30. 30.
    Nagy LE (2015) The role of innate immunity in alcoholic liver disease. Alcohol Res 37:237–250Google Scholar
  31. 31.
    Olsson I, Mykletun A, Dahl AA (2005) The Hospital Anxiety and Depression Rating Scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry 5:46.  https://doi.org/10.1186/1471-244x-5-46 CrossRefGoogle Scholar
  32. 32.
    Perricone C, De Carolis C, Perricone R (2009) Glutathione: a key player in autoimmunity. Autoimmun Rev 8:697–701.  https://doi.org/10.1016/j.autrev.2009.02.020 CrossRefGoogle Scholar
  33. 33.
    Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194–199.  https://doi.org/10.1159/000083509 CrossRefGoogle Scholar
  34. 34.
    Segal BM, Thomas W, Zhu X, Diebes A, McElvain G, Baechler E et al (2012) Oxidative stress and fatigue in systemic lupus erythematosus. Lupus 21:984–992.  https://doi.org/10.1177/0961203312444772 CrossRefGoogle Scholar
  35. 35.
    Seljeskog E, Hervig T, Mansoor MA (2006) A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin Biochem 39:947–954.  https://doi.org/10.1016/j.clinbiochem.2006.03.012 CrossRefGoogle Scholar
  36. 36.
    Setty AR, Curhan G, Choi HK (2007) Smoking and the risk of psoriasis in women: nurses’ health study II. Am J Med 120:953–959.  https://doi.org/10.1016/j.amjmed.2007.06.020 CrossRefGoogle Scholar
  37. 37.
    Shrestha A, Bahce-Altuntas A, Mowrey W, Broder A (2016) Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum 46:286–290.  https://doi.org/10.1016/j.semarthrit.2016.05.011 CrossRefGoogle Scholar
  38. 38.
    Sikar Akturk A, Ozdogan HK, Bayramgurler D, Cekmen MB, Bilen N, Kiran R (2012) Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. J Eur Acad Dermatol Venereol 26:833–837.  https://doi.org/10.1111/j.1468-3083.2011.04164.x CrossRefGoogle Scholar
  39. 39.
    Skoie IM, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K et al (2017) Fatigue in psoriasis: a controlled study. Br J Dermatol 177(2):505–512.  https://doi.org/10.1111/bjd.15375 CrossRefGoogle Scholar
  40. 40.
    Surowiec I, Gjesdal CG, Jonsson G, Norheim KB, Lundstedt T, Trygg J et al (2016) Metabolomics study of fatigue in patients with rheumatoid arthritis naive to biological treatment. Rheumatol Int 36:703–711.  https://doi.org/10.1007/s00296-016-3426-2 CrossRefGoogle Scholar
  41. 41.
    Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS et al (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76:377–390.  https://doi.org/10.1016/j.jaad.2016.07.064 CrossRefGoogle Scholar
  42. 42.
    Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P et al (2007) Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 379:87–94.  https://doi.org/10.1016/j.cca.2006.12.026 CrossRefGoogle Scholar
  43. 43.
    Van Dyke BR, Saltman P (1996) Hemoglobin: a mechanism for the generation of hydroxyl radicals. Free Radic Biol Med 20:985–989CrossRefGoogle Scholar
  44. 44.
    Vina J, Sastre J, Pallardo FV, Gambini J, Borras C (2006) Role of mitochondrial oxidative stress to explain the different longevity between genders: protective effect of estrogens. Free Radic Res 40:1359–1365.  https://doi.org/10.1080/10715760600952851 CrossRefGoogle Scholar
  45. 45.
    Wang Z, Wang Y, Liu H, Che Y, Xu Y, Lingling E (2015) Age-related variations of protein carbonyls in human saliva and plasma: is saliva protein carbonyls an alternative biomarker of aging? Age (Dordr) 37:9781.  https://doi.org/10.1007/s11357-015-9781-1 Google Scholar
  46. 46.
    Wolfe F (2004) Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 31:1896–1902Google Scholar
  47. 47.
    Wozniak A, Drewa G, Krzyzynska-Malinowska E, Czajkowski R, Protas-Drozd F, Mila-Kierzenkowska C et al (2007) Oxidant-antioxidant balance in patients with psoriasis. Med Sci Monit 13:CR30–CR33Google Scholar
  48. 48.
    Yagi K (1998) Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 108:101–106.  https://doi.org/10.1385/0-89603-472-0:101 Google Scholar
  49. 49.
    Yazici C, Kose K, Utas S, Tanrikulu E, Taslidere N (2016) A novel approach in psoriasis: first usage of known protein oxidation markers to prove oxidative stress. Arch Dermatol Res 308:207–212.  https://doi.org/10.1007/s00403-016-1624-0 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of DermatologyStavanger University HospitalStavangerNorway
  2. 2.Section of Biostatistics, Research DepartmentStavanger University HospitalStavangerNorway
  3. 3.Clinical Immunology Unit, Department of Internal MedicineStavanger University HospitalStavangerNorway
  4. 4.Department of Clinical Science, Faculty of MedicineUniversity of BergenBergenNorway
  5. 5.Department of Medical BiochemistryStavanger University HospitalStavangerNorway

Personalised recommendations